GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (NAS:FTRE) » Definitions » Cash Conversion Cycle

Fortrea Holdings (Fortrea Holdings) Cash Conversion Cycle : 76.24 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Fortrea Holdings Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Fortrea Holdings's Days Sales Outstanding for the three months ended in Mar. 2024 was 97.99.
Fortrea Holdings's Days Inventory for the three months ended in Mar. 2024 was 0.
Fortrea Holdings's Days Payable for the three months ended in Mar. 2024 was 21.75.
Therefore, Fortrea Holdings's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 76.24.


Fortrea Holdings Cash Conversion Cycle Historical Data

The historical data trend for Fortrea Holdings's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortrea Holdings Cash Conversion Cycle Chart

Fortrea Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
- 41.44 40.79 39.49

Fortrea Holdings Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 41.58 36.89 36.22 37.71 76.24

Competitive Comparison of Fortrea Holdings's Cash Conversion Cycle

For the Biotechnology subindustry, Fortrea Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortrea Holdings's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortrea Holdings's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Fortrea Holdings's Cash Conversion Cycle falls into.



Fortrea Holdings Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Fortrea Holdings's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=54.6+0-15.11
=39.49

Fortrea Holdings's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=97.99+0-21.75
=76.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fortrea Holdings  (NAS:FTRE) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Fortrea Holdings Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Fortrea Holdings's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortrea Holdings (Fortrea Holdings) Business Description

Traded in Other Exchanges
Address
8 Moore Drive, Durham, NC, USA, 27709
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Executives
Thomas Pike officer: Chief Executive Officer C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601
Peter M Neupert director 13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005
Betty D Larson director GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE, CHICAGO IL 60661
R Andrew Eckert director THREE RAVINIA DRIVE, ATLANTA GA 30346
Edward A Pesicka director 9120 LOCKWOOD BLVD, MECHANICSVILLE VA 23116
Amrit Ray director 60 LEVERONI COURT, NOVATO CA 94949
Amanda M. Warren officer: Chief Accounting Officer 8 MOORE DRIVE, DURHAM NC 27703
David Ross Smith director 251 BALLARDVALE STREET, WILMINGTON MA 01887
Van Der Vaart Sandra D director, officer: President and Secretary 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg director, officer: Executive Vice President P O BOX 1017, CHARLOTTE NC 28201-1017
James S. Hanson officer: General Counsel 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Laboratory Corp Of America Holdings 10 percent owner 358 S MAIN ST, BURLINGTON NC 27215
Jill G. Mcconnell officer: Chief Financial Officer 8 MOORE DRIVE, DURHAM NC 27703
Mark A. Morais officer: Chief Operating Officer 8 MOORE DRIVE, DURHAM NC 27703
Robert S. Pringle officer: Treasurer 531 SOUTH SPRING STREET, BURLINGTON NC 27215